
Chief Executive Officer at Xceleron Inc
Greater Philadelphia Area

Chief Executive Officer at Xceleron Inc
Greater Philadelphia Area
Michael Butler, Ph.D. is a general manager with a strategic client and operations focus in the global drug development industry. He has 20 years experience in science-driven businesses in Europe, US and Asia and is energized by the organizational challenges at the interface of science and business.
Most recently, Mike was the President, Scientific Operations and Chief Scientific Officer with Aptuit. During an acquisition-driven expansion, he consolidated and integrated API, preclinical, formulation, solid state chemistry and drug product manufacturing operations. The organization grew from three locations to eight and employed 800+ staff. Mike also led efforts to penetrate large accounts using Strategic Alliance Management teams, allocated R&D investment in service-oriented solutions and managed the Scientific Advisory Board. Mike was a member of the Aptuit-Laurus Board of Directors.
Before Aptuit, he was Group Vice President at MDS Pharma Services where he managed the company’s largest operations and commercial organizations. Ten clinical and chemistry operating units were located in N. America and Europe with clients in N. America, Europe and Asia. Prior to MDS, Mike was the Group Director, Business Development for Huntingdon Life Sciences. At Huntingdon, he over-saw the segmentation and growth of all drug development business in Europe, N America, S. Korea and Japan.
Throughout his career, Mike has maintained a focus on the needs of his clients and has helped develop services in discovery optimization, immunomodulation, biomarker measurement and integrated early development project management.
Mike attended Heriot Watt University from which he holds a B.Sc. (Hons) degree and the University of Liverpool where he earned his Ph.D.
Driving revenue growth
Fostering deep client rapport
Creating scalable operations organizational structures
(Privately Held; Biotechnology industry)
December 2008 — Present (1 year )
(Privately Held; 1001-5000 employees; Pharmaceuticals industry)
December 2007 — December 2008 (1 year 1 month)
Promoted to lead Aptuit’s organic business growth phase. Driven by scientific innovation, integrated development services and Strategic Alliance Management teams to penetrate the world’s largest pharmaceutical companies. Responsibility included N. America, Europe and India
(Privately Held; 1001-5000 employees; Biotechnology industry)
April 2006 — December 2007 (1 year 9 months)
Hired to lead business during aggressive acquisition program in N America and Europe. Scientific Operations grew from three locations with $75MM in revenues to eight with $200MM in revenues. Operations included API manufacture, GMP analytical, formulation, drug product manufacture, solid state chemistry and GLP safety assessment.
(Public Company; Biotechnology industry)
April 2002 — April 2006 (4 years 1 month)
(Public Company; Pharmaceuticals industry)
1995 — 2002 (7 years )
(Pharmaceuticals industry)
1992 — 1995 (3 years )
Ph.D. , 1984 — 1987
B.Sc. , 1980 — 1984
Industry roundtable